Travere Therapeutics Cash Flow Statement
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
52.13+0.085 (+0.16%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Travere Therapeutics free cash flow
In fiscal 2025, Travere Therapeutics generated $37.8 million of operating cash flow. That left free cash flow of $37.8 million, a free-cash-flow margin of 7.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Travere Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -25.55M | -321.55M | -111.40M | -278.48M | -180.09M | -169.43M | -146.43M | -102.68M | -59.73M | -47.90M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | -140.86% |
| Depreciation & Amortization | 60.74M | 43.55M | 38.53M | 20.72M | 12.75M | 24.58M | 20.41M | 18.67M | 17.80M | 16.14M |
| Stock-Based Compensation | 44.87M | 36.91M | 44.25M | 38.14M | 29.57M | 23.61M | 21.11M | 19.77M | 26.87M | 29.10M |
| Change in Working Capital | -43.06M | -30.97M | -46.77M | -19.70M | 41.72M | -13.51M | 2.32M | -6.69M | 2.60M | -12.02M |
| Operating Cash Flow | 37.78M | -237.47M | -280.02M | -186.29M | -14.79M | -42.74M | -58.21M | -24.96M | 7.40M | -3.44M |
| Capital Expenditures | — | — | -668.00K | -191.00K | -5.10M | -6.77M | -195.00K | -727.00K | -887.00K | -1.43M |
| Investing Cash Flow | 27.89M | 99.33M | 55.78M | -32.55M | -137.62M | -61.33M | 19.86M | -203.29M | 45.60M | 10.37M |
| Share Repurchases | — | — | — | — | — | — | — | — | — | 0 |
| Debt Repaid | — | — | — | — | — | 0 | 0 | -40.20M | 0 | 0 |
| Financing Cash Flow | -33.47M | 139.42M | 218.75M | 117.57M | 231.68M | 127.71M | -2.08M | 231.86M | 5.45M | -3.85M |
| Net Change in Cash | 34.50M | 359.00K | -3.51M | -104.06M | 80.98M | 22.34M | -40.44M | 3.48M | 58.39M | 3.20M |
| Free Cash Flow | 37.78M | -237.47M | -280.69M | -186.48M | -19.89M | -49.51M | -58.41M | -25.68M | 6.52M | -4.87M |
This table shows 10 annual periods of Travere Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TVTX's reporting calendar. What is a cash flow statement?